ArticleJournal of clinical medicine2021
The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Changes in accommodation and vergence parameters with topical use of 0.025% and 0.05% atropine in myopes aged between 7 and 17 years.Eye (London, England) · 2025Trial
- Effect of low-dose atropine eyedrops on pupil metrics: results after half a year of treatment and cessation.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Trial
- Progression with myopia control spectacles: identifying predictors of response to defocus incorporated multiple segment and highly aspherical lenslets spectacles in the French myopia cohort.BMJ open ophthalmology · 2026Article
- Microbial and Chemical Stability of Unpreserved Atropine Sulfate 0.01%Life (Basel, Switzerland) · 2025Article
- Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye.Turkish journal of ophthalmology · 2025Article
- Myopi-X lenses vs. low-dose atropine in myopia control: a Turkish retrospective study : Study design: retrospective observational study.BMC ophthalmology · 2025Observational
- Myopia control efficacy of peripheral defocus modifying spectacle lenses in children and adolescents: a Meta-analysis.International journal of ophthalmology · 2025Article
- The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions.Journal of clinical medicine · 2023Review
- Article
- Is 0.01% Atropine an Effective and Safe Treatment for Myopic Children? A Systemic Review and Meta-Analysis.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Myopia will affect half the global population by 2050 and is a leading cause of vision impairment. High-dose atropine slows myopia progression but with undesirable side-effects. Low-dose atropine is an alternative. We report the effects of 0.01% or 0.005% atropine eye drops on myopia progression in 13 Australian children aged between 2 and 18 years and observed for 2 years without and up to 5 years (mean 2.8 years) with treatment. Prior to treatment, myopia progression was either 'slow' (more positive than -0.5 D/year; mean -0.19 D/year) or 'fast' (more negative than -0.5 D/year; mean -1.01 D/year). Atropine reduced myopic progression rates (slow: -0.07 D/year, fast: -0.25 D/year, combined: before: -0.74, during: -0.18 D/year,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.